Skip to content

Bob Uger

Bob Uger

Company: Trillium Therapeutics

Job title: Chief Scientific Officer


Dr. Uger has spent the past 18 years developing novel agents targeting the immune system. He began his industry career in cancer vaccine research with Aventis Pasteur, and then joined start-up Trillium Therapeutics (private company) as Director, Research & Development, later serving as Vice President, R & D. At Trillium, Dr. Uger has overseen the growth of the company’s pipeline and guided several compounds from concept to the clinic. His expertise spans innate and adaptive immunology, and he has overseen programs in the fields of immuno-oncology, autoimmunity and transplantation. He received his Ph.D. in immunology from the University of Toronto.


Targeting the CD47 “Do Not Eat” Signal with TTI-621 (SIRPa-IgG1 Fc) 9:30 am

• Evaluate TTI-621, a dual function SIRPaFc decoy receptor that inhibits the CD47 “do not eat” signal and delivers an activating signal to macrophages through Fc receptors • Review how TTI-621 is differentiated from other CD47 blocking agents in development • Discuss emerging clinical dataRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.